HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

502.512

+19.3574.01%

Number of Gainers:24

Number of Losers:6

Number of Flat:3

PE:- -

High:504.211

Open:483.278

Low:478.821

Close:483.155

Volume:109.56M

Turnover:3.00B

Market Cap:318.64B

Float Cap:283.64B

Loading ...

Ascletis Hits 4-Week High on Initiating US Phase I Study on Obesity Drug

How Traditional Chinese Medicine Is Moving From Ancient Recipes to Evidence-Based Data

TYK Medicines-B Chairman, President and CEO Wu Yusheng Plans Share Purchase

HBM Holdings' Asthma Therapy Shows Promising Phase II Results and Moves to Phase III

Chengdu Easton Biopharmaceuticals Schedules Participation in Semi-Annual Innovation Drug Sector Earnings Call

HBM Says Partner Windward Bio Starts Phase 3 Asthma Trial of Twice-Yearly TSLP Antibody Hbm9378/win378

Hbm9378/Win378, an Ultra-Long-Acting Antibody Targeting Tslp, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study

THOMSON REUTERS

Genfleet-B Completes Share Buyback Worth HK$1.54 Million

The AI Drug Discovery Sector Enters Its Value-Realization Phase, Unlocking Fresh Growth Avenues for Innovative Medicines

ALEBUND-B Wins US FDA Nod to Start Trial of Novel IgA Nephropathy Drug AP308

Alphamab-B Repurchases 220,000 Shares for HK$1.85 Million on September 8

Alphamab Oncology Files HKEX Next-Day Return Disclosing Share Repurchase at HKD 8.41

Ionis Pharmaceuticals Shares Slide 13.1% in Pre-Market Trading

ASC36 Obesity Therapy Enters Phase I Trials in the US by Ascletis

Ascletis Pharma - Initiates U.S. Phase I Study for Asc36 Oral Tablets for Obesity

THOMSON REUTERS

Consolidation at the Base Meets Trend Rebound: When Will Kintor Pharma-B Hit the Key Turning Point for a Valuation Recovery?

Nanxin Pharmaceutical Receives Penalty for Disclosure Violations, Affected Investors May Seek Compensation

InnoCare Gets First Half of Remaining Stake Bought in Subsidiary

MT Newswires Live

HK Market Alert: Biocytogen-B (02315) Surges Over 10% in Afternoon Trade Following Exclusive Licensing Agreement with Qilu Pharmaceutical

Hong Kong Market Pulse | CRO Shares Advance as Order Growth Strengthens; AI-Enabled Drug Discovery Poised to Transform Pharma R&D

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/BK1574/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":502.51205,"timestamp":1789373282104,"preClose":483.15506,"halted":0,"volume":109559454,"delay":0,"changeRate":0.040064,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":19.356995,"latestTime":"09-14 16:00:00","open":483.2777,"high":504.2106,"low":478.82104,"amount":2997572701.5,"amplitude":0.05255,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789435800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789349400000,1789358400000],[1789362000000,1789372800000]],"pbRate":3.606253,"peRate":160.422718,"turnoverRate":0.004111,"increases":23,"decrements":7,"flats":2,"marketCap":318641943840,"floatMarketCap":283642599432},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":504.2106,"amplitude":0.05255,"preClose":483.15506,"low":478.82104,"pbRate":"3.606253","latestPrice":502.51205,"volume":109559454,"delay":0,"open":483.2777,"prevYearClose":556.26263,"prevWeekClose":483.155,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":516.325,"twentyDayClose":505.128,"sixtyDayClose":444.911,"secType":"PLATE","market":"HK","turnoverRate":0.004111,"peRate":160.422718,"marketCap":318641943840,"floatMarketCap":283642599432,"timestamp":1789373282104,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":24,"down":6,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666309337","title":"Ascletis Hits 4-Week High on Initiating US Phase I Study on Obesity Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2666309337","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666309337?lang=en_us&edition=fundamental","pubTime":"2026-09-09 10:03","pubTimestamp":1788919398,"startTime":"0","endTime":"0","summary":"BUZZ-Ascletis hits 4-week high on initiating US Phase I study on obesity drug** Shares of Ascletis Pharma Inc1672.HKclimb 5.6% to HK$10.75, their highest since August 13** Stock on track for biggest one-day pct gain since August 7** Pharmaceutical products producer says it hasinitiateda U.S. Phase I study of ASC36 oral tablets for treatment of obesity after receiving Investigational New Drug clearance from the U.S. Food and Drug Administration** ASC36 oral tablets reduced mean body weight up to 13.2% from baseline after once-daily dosing for seven days in non-human primates - co** YTD, stock down 7.3%, while Hang Seng Biotech Index.HSBIOup 10.7%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nL1N451020:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1515","01672","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186275720","title":"How Traditional Chinese Medicine Is Moving From Ancient Recipes to Evidence-Based Data","url":"https://stock-news.laohu8.com/highlight/detail?id=1186275720","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186275720?lang=en_us&edition=fundamental","pubTime":"2026-09-09 07:41","pubTimestamp":1788910867,"startTime":"0","endTime":"0","summary":"Traditional Chinese Medicine (TCM) has long been built on the accumulated wisdom of generations of physicians. However, when measured against the rigorous standards of modern medicine, the industry...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","MEDX","BK4159","BK1161","RCT","IBBQ","LNGR","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136667600","title":"TYK Medicines-B Chairman, President and CEO Wu Yusheng Plans Share Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=1136667600","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136667600?lang=en_us&edition=fundamental","pubTime":"2026-09-08 21:26","pubTimestamp":1788873985,"startTime":"0","endTime":"0","summary":"TYK Medicines-B (02410) has announced that its Chairman, Executive Director and President, Dr. Wu Yusheng, has informed the company of his recent share purchases in the open market. Dr. Wu may...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1161","BK1574","09939","159938","02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167922243","title":"HBM Holdings' Asthma Therapy Shows Promising Phase II Results and Moves to Phase III","url":"https://stock-news.laohu8.com/highlight/detail?id=1167922243","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167922243?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:58","pubTimestamp":1788872333,"startTime":"0","endTime":"0","summary":"HBM HOLDINGS-B (02142) has announced that its partner, Windward Bio AG, has reported positive interim results from the Phase II portion of the POLARIS-1 clinical trial evaluating HBM9378/WIN378 for...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02142","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154956841","title":"Chengdu Easton Biopharmaceuticals Schedules Participation in Semi-Annual Innovation Drug Sector Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=1154956841","media":"Deep News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154956841?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:52","pubTimestamp":1788871964,"startTime":"0","endTime":"0","summary":"Chengdu Easton Biopharmaceuticals Co.,Ltd. (SSE: 688513) announced on September 8 that it will take part in the Science and Technology Innovation Board's collective earnings briefing for the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","BK1574","MEDX","IBBQ","LNGR","688513","KSTR","06978","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320273","title":"HBM Says Partner Windward Bio Starts Phase 3 Asthma Trial of Twice-Yearly TSLP Antibody Hbm9378/win378","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320273","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320273?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:18","pubTimestamp":1788869907,"startTime":"0","endTime":"0","summary":"HBM says partner Windward Bio starts Phase 3 asthma trial of twice-yearly TSLP antibody HBM9378/WIN378HBM Holdings highlighted positive interim Phase 2 asthma results for HBM9378/WIN378, an ultra-long","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL4WknG1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","02142","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320213","title":"Hbm9378/Win378, an Ultra-Long-Acting Antibody Targeting Tslp, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320213","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320213?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:17","pubTimestamp":1788869848,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA60HVBV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02142","BK1574","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126663144","title":"Genfleet-B Completes Share Buyback Worth HK$1.54 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1126663144","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126663144?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:11","pubTimestamp":1788869514,"startTime":"0","endTime":"0","summary":"On September 8, 2026, GENFLEET-B (02595) announced that it had repurchased a total of 57,000 shares at a cost of HK$1.5418 million.The buyback was executed in accordance with the company's existing...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1515","BK1161","02595","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190517580","title":"The AI Drug Discovery Sector Enters Its Value-Realization Phase, Unlocking Fresh Growth Avenues for Innovative Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=1190517580","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190517580?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:10","pubTimestamp":1788869456,"startTime":"0","endTime":"0","summary":"The AI-driven pharmaceutical industry has moved past its early-stage concept hype, with validation levels steadily climbing. The narrative has shifted from algorithmic promise to tangible pipeline...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","IBBQ","VTHR","01477","AGIX","CHAT","LNGR","AIPO","BK1191","BK1161","MEDX","QTOC","159992","ARTY","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141807270","title":"ALEBUND-B Wins US FDA Nod to Start Trial of Novel IgA Nephropathy Drug AP308","url":"https://stock-news.laohu8.com/highlight/detail?id=1141807270","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141807270?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:06","pubTimestamp":1788869176,"startTime":"0","endTime":"0","summary":"ALEBUND-B (09637) has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AP308, a first-in-class engineered recombinant IgA...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","BMED","BK1191","BK1515","PSYK","BK1161","MDTX","IBBJ","IBBQ","BK1574","159151","09637","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175433190","title":"Alphamab-B Repurchases 220,000 Shares for HK$1.85 Million on September 8","url":"https://stock-news.laohu8.com/highlight/detail?id=1175433190","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175433190?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:28","pubTimestamp":1788866893,"startTime":"0","endTime":"0","summary":"ALPHAMAB-B (09966) announced that it spent HK$1.8499 million to buy back 220,000 shares on September 8, 2026.The repurchase reflects the company's ongoing commitment to enhancing shareholder value through strategic capital management initiatives.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665323327","title":"Alphamab Oncology Files HKEX Next-Day Return Disclosing Share Repurchase at HKD 8.41","url":"https://stock-news.laohu8.com/highlight/detail?id=2665323327","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665323327?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:25","pubTimestamp":1788866733,"startTime":"0","endTime":"0","summary":"Alphamab Oncology files HKEX next-day return disclosing share repurchase at HKD 8.41Alphamab Oncology repurchased 220,000 shares on Sept. 8 for treasury, no cancellations disclosed.Buyback price range","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL8Tygqr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143453518","title":"Ionis Pharmaceuticals Shares Slide 13.1% in Pre-Market Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1143453518","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143453518?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:20","pubTimestamp":1788866449,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals shares dropped 13.1% in pre-market trading on September 8, according to market data.  The decline reflects a sharp investor reaction to recent developments, though specific...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1191","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164928784","title":"ASC36 Obesity Therapy Enters Phase I Trials in the US by Ascletis","url":"https://stock-news.laohu8.com/highlight/detail?id=1164928784","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164928784?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:06","pubTimestamp":1788861983,"startTime":"0","endTime":"0","summary":"Ascletis Pharma-B (01672) has announced the initiation of its Phase I clinical study in the United States for ASC36, an oral amylin receptor agonist peptide designed to treat obesity, following...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1515","BK1161","01672","01477","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665932180","title":"Ascletis Pharma - Initiates U.S. Phase I Study for Asc36 Oral Tablets for Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2665932180","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665932180?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:01","pubTimestamp":1788861676,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nFWN44Z0L3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01672","BK1161","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150107003","title":"Consolidation at the Base Meets Trend Rebound: When Will Kintor Pharma-B Hit the Key Turning Point for a Valuation Recovery?","url":"https://stock-news.laohu8.com/highlight/detail?id=1150107003","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150107003?lang=en_us&edition=fundamental","pubTime":"2026-09-08 16:48","pubTimestamp":1788857312,"startTime":"0","endTime":"0","summary":"On the morning of September 7, KINTOR PHARMA-B (09939) announced that its human long-term safety trial for KT-939, a novel and highly effective tyrosinase inhibitor developed in-house to suppress...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1515","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101281013","title":"Nanxin Pharmaceutical Receives Penalty for Disclosure Violations, Affected Investors May Seek Compensation","url":"https://stock-news.laohu8.com/highlight/detail?id=1101281013","media":"Deep News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101281013?lang=en_us&edition=fundamental","pubTime":"2026-09-08 15:31","pubTimestamp":1788852662,"startTime":"0","endTime":"0","summary":"Nanxin Pharmaceutical has been found to have disclosed inaccurate financial data in its annual report. On August 13, 2026, the company officially received the Administrative Penalty Decision issued...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","01477","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665476053","title":"InnoCare Gets First Half of Remaining Stake Bought in Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2665476053","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665476053?lang=en_us&edition=fundamental","pubTime":"2026-09-08 14:15","pubTimestamp":1788848135,"startTime":"0","endTime":"0","summary":"InnoCare Pharma  received the first half of the 7% stake of Guangzhou InnoCare Pharma Technology, according to a Shanghai bourse filing on Tuesday.Guangzhou InnoCare completed the changes in its industry and commerce registration after its parent received its 3.5% stake.InnoCare bought the remaining 7% of Guangzhou InnoCare for 476.3 million yuan in August.The pharmaceutical company's shares slipped 1% during the afternoon trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688428","BK1574","BK0239","BK1161","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170187220","title":"HK Market Alert: Biocytogen-B (02315) Surges Over 10% in Afternoon Trade Following Exclusive Licensing Agreement with Qilu Pharmaceutical","url":"https://stock-news.laohu8.com/highlight/detail?id=1170187220","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170187220?lang=en_us&edition=fundamental","pubTime":"2026-09-08 14:00","pubTimestamp":1788847256,"startTime":"0","endTime":"0","summary":"Biocytogen-B (02315) saw its shares jump more than 10% in the afternoon session, last trading up 8.71% at HK$63 with turnover reaching HK$129 million.According to the company's official WeChat...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK4588","688796","BK4585","01477","VXUS","BK1191","KCAI","BK0216","BK1161","02315"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134077786","title":"Hong Kong Market Pulse | CRO Shares Advance as Order Growth Strengthens; AI-Enabled Drug Discovery Poised to Transform Pharma R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=1134077786","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134077786?lang=en_us&edition=fundamental","pubTime":"2026-09-08 13:50","pubTimestamp":1788846618,"startTime":"0","endTime":"0","summary":"CRO-related stocks extended their upward momentum into the afternoon session, with Genscript Bio (01548) surging 10.71% to HK$34.32, Asymchem (06821) climbing 8.5% to HK$142.90, Tigermed (03347)...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","ARTY","JHMH","BK1583","BK4588","HK0000320264.USD","AIPO","BK1191","03347","VTHR","BK1141","03759","01548","HK0000306685.HKD","LRND","CHAT","QTOC","KCAI","VXUS","BK4585","AGIX","HK0000320223.HKD","06821","BK1576","01477","BME","HK0000306701.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":12,"pageCount":6,"totalSize":238,"code":"91000000","status":"200"}]}}